Favipiravir
Favipiravir (T-705), a guanine analogue,effectively inhibits the
RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola,
yellow fever, chikungunya, norovirus and enterovirus, adding a recent
study, reported its activity against 2019-nCoV [10]. Patients with
2019-nCoV are being recruited in randomized trials to evaluate the
efficacy of favipiravir plus interferon-α (ChiCTR2000029600) and
favipiravir plus baloxavirmarboxil (an approved influenza inhibitor
targeting the cap-dependent endonuclease) (ChiCTR2000029544) [13].
Although, EC50 value of Favipiravir in Vero E6 cells was as high as 67
μM. It was reported to reduce viral infection of 2019-nCoV in (EC50 =
61.88 μM, CC50 > 400 μM, SI > 6.46)
concentrations [14] suggesting further in vivo studies to be
screened against 2019-nCoV to test the efficacy of this antiviral
nucleoside.